-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Lianhuan Pharmaceutical (600513.SH) issued an announcement. Recently, the company received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for the active ingredient bilastine issued by the State Drug Administration. Bilastine is a non-sedative long-acting antihistamine that selectively antagonizes peripheral H1 receptors, and has no affinity for muscarinic receptors and low affinity for other receptors.
Share
Listen to the news
Zhitong Finance App News, Lianhuan Pharmaceutical (600513.SH) issued an announcement. Recently, the company received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for the active ingredient bilastine issued by the State Drug Administration. Bilastine is a non-sedative long-acting antihistamine that selectively antagonizes peripheral H1 receptors, and has no affinity for muscarinic receptors and low affinity for other receptors.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending